排名前五的靶点	数量

A3R(腺苷A3受体)	5
CFL1(cofilin 1)	2
CCR2(C-C趋化因子受体2型)	1
BUB1(BUB1 mitotic checkpoint serine/threonine kinase)	1
USP18(ubiquitin specific peptidase 18)	1

关联

项与 University of Leiden 相关的药物

LEI-401

靶点

NAPE-PLD

作用机制

NAPE-PLD 抑制剂

在研机构

University of Leiden

原研机构

University of Leiden

在研适应症

肥胖 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Tridecaptin analogues Oct-His9(Leiden University)

靶点-

作用机制-

在研机构

University of Leiden

原研机构

University of Leiden

在研适应症

铜绿假单胞菌感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

EVG7

靶点-

作用机制-

在研机构

University of Leiden

原研机构

University of Leiden

在研适应症

艰难梭菌感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

109

项与 University of Leiden 相关的临床试验

NCT06862453

/ Recruiting临床1期

Safety, Tolerability and Efficacy Against Controlled Human Malaria Infection of PfSPZ-LARC2 Vaccine in Malaria-naïve Adults

This is a first-in-human, randomized, double-blind, placebo-controlled Phase 1 trial of Plasmodium falciparum (Pf) sporozoite (SPZ) late-arresting replication-competent (LARC) malaria vaccine (PfSPZ-LARC2 Vaccine) administered to healthy, malaria-naive study participants in Germany by direct venous inoculation (DVI) to determine safety, tolerability, and vaccine efficacy (VE) against controlled human malaria infection (CHMI). PfSPZ-LARC2 Vaccine contains a deletion of two genes, the Mei2 and LINUP genes, and undergoes developmental arrest in the late liver stages without releasing merozoites into the blood stream (blood stage parasites).
The primary objective of the study is to assess the safety and tolerability of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation, in the intention-to-treat (ITT) population.
Studies of PfSPZ-LARC2 in FRG mice indicate that Plasmodium falciparum LARC2 parasites halt development in their late liver life cycle stages and do not generate viable merozoites able to initiate blood stage infection. Attenuation in this assay system has been a good predictor of attenuation in humans, indicating that blood stage infection in this trial of PfSPZ-LARC2 Vaccine will not occur. Recent data from Leiden University where a Mei2 single deletion parasite was administered to human participants by mosquito bite confirmed that removing this single gene by itself confers complete attenuation. PfSPZ-LARC2 Vaccine has both Mei2 and LINUP deleted, so it should be completely attenuated.
In order to better understand what side effects might look like, on the small chance that PfSPZ-LARC2 Vaccine is not adequately attenuated, it is important to briefly describe the safety data from studies of PfSPZ-CVac (chloroquine), a whole Plasmodium falciparum sporozoite (PfSPZ) immunization approach that uses cGMP produced, aseptic, purified, cryopreserved, non-attenuated, fully infectious PfSPZ administered under chloroquine cover. This is because the safety and tolerability data from PfSPZ-CVac represent a worst case scenario for what could happen with PfSPZ-LARC2 Vaccine with respect to safety and tolerability, as recipients of PfSPZ-CVac always have blood stage infection after the first immunization, even if small doses are administered. The current standard regimen in malaria-naive adults receiving PfSPZ-CVac is 2.0x10^5 PfSPZ, 62.5-fold higher than the 100% infective dose for controlled human malaria infection (CHMI) in malaria-naive individuals, which is 3.2x10^3 PfSPZ. The blood stage infection is detectable by ultrasensitive qPCR on days 7 to 9 after PfSPZ administration and then clears due to the schizonticidal action of chloroquine. Doses used for PfSPZ-CVac have been escalated to as high as 2x10^5 PfSPZ in malaria-naive adults and 4.0x10^5 PfSPZ in malaria-exposed adults, and are generally well tolerated; however, some individuals experienced symptoms of malaria on days 7 and 8 during the period of transient parasitemia, including Grade 3 adverse events, which can largely be prevented by the administration of drugs such as ibuprofen, naproxen or acetaminophen starting the morning of day 7 or after symptoms appear. Once the first dose of 2x10^5 PfSPZ is administered, immunity develops rapidly, and when the second and third doses are administered at 4-week intervals, there have been no Grade 3 adverse events recorded even in the absence of ibuprofen, naproxen or acetaminophen.
These data from PfSPZ-CVac are relevant because they represent a possible worst-case scenario for PfSPZ-LARC2 Vaccine. In other words, even if the attenuation of PfSPZ-LARC2 parasites is not realized in vivo, the density of parasitemia should not be any higher nor the tolerability any worse than what has already been experienced with non-attenuated PfSPZ-CVac administered at the same PfSPZ dose. On the contrary, we would expect the percentage of participants with a blood stage infection to be lower following PfSPZ-LARC2 Vaccine administration due to its intrinsic attenuation than with non-attenuated PfSPZ, and in individuals with a blood stage infection, the numbers of parasites released from the liver to be lower than with non-attenuated PfSPZ.
This will be the first assessment of PfSPZ-LARC2 Vaccine in humans. While we anticipate that vaccine efficacy (VE) in humans will be similar to that of PfSPZ-CVac, we have no data at this point, and it will be important to collect these comparative data. However, in the Leiden trial, where the Mei2 single knockout called GA2 was administered by mosquito bite, there was good protection after 3 immunizations by exposure to 50 infected mosquitoes (8/9 participants protected against homologous CHMI using 5 infected mosquitoes).

开始日期2026-04-01

申办/合作机构

Sanaria, Inc.

[+2]

NCT07294794

/ Not yet recruitingN/A

Personalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension (HYPERMARKER)

High blood pressure (hypertension) affects 1 in 3 adults and can lead to serious health issues like strokes and heart attacks. Medication can lower blood pressure (BP) and reduce complications. Choosing the right medication can be challenging, potentially leading to side effects or poor control.
HYPERMARKER is testing whether providing doctors with additional information when they make a blood pressure prescription choice can improve a patient's overall blood pressure management. This includes relevant clinical information and personalised results from blood tests, brought together using computer programs (machine learning)- 'smart approach'. The blood tests check for small substances naturally produced by the body called metabolites
Developed with patient and public involvement, this proof-of-concept clinical trial will recruit 400 people across four sites in the UK, Spain, the Netherlands, and Germany. Participants must have a recent high blood pressure reading with a clinical need for medication. After providing written consent, they will provide a blood sample (to measure their metabolites) and receive a BP monitor connected to a smartphone app allowing them to measure and record their BP at home throughout the trial.
The study's main outcome is home BP readings. Participants will also complete web-based questionnaires about their health, diet, treatment experience, and healthcare usage.
Participants will be randomly assigned to two groups. Group A will receive medication based on standard clinical practice up-front, then investigators will receive output from the smart approach to refine the choice of treatment. In Group B, investigators will receive the output from the 'smart approach' initially, with further updates provided later.
Only medications licensed for hypertension will be used. All prescriptions are determined by clinicians throughout the trial.
The trial lasts 9-16 weeks. At the end, participants and their usual doctor get a copy of their BP readings and medication to guide their long-term care.

开始日期2026-01-19

申办/合作机构

University of Birmingham

[+1]

NCT07157358

/ RecruitingN/AIIT

Online Medical Hypnosis Exercises to Improve Mental Health in Primary School Children and Prevent Future Mental Health Issues

The goal of this trial is to learn if listening daily to online hypnosis exercises helps to improve mental health and self-esteem in primary school children. In the future we also hope to see if it can prevent feelings of depession or anxiety when these children have become teenagers.
The main questions it aims to answer are:
1. can daily listening to these exercsies improve self-esteem, resilience and mental health of children 10-11 years compared to children who do not listen to these exercises?
2. can listening to these exercsies prevent future metal health problems like feelings of depression or anxiety.
Researchers will compare a group of children (10-11 years) who will listen daily to the exercises for 2 months with a group who will do that 6 months later.
Participants will:
Listen daily to a hypnosis exercise of maximum 15 minutes. Fill out questionnaires on self-esteem, resilience and mental health before during and after the study.

开始日期2025-07-31

申办/合作机构

St.-Antonius-Hospital gGmbH

[+1]

100 项与 University of Leiden 相关的临床结果

登录后查看更多信息

0 项与 University of Leiden 相关的专利（医药）

登录后查看更多信息

20,076

项与 University of Leiden 相关的文献（医药）

2026-12-31·Global Public Health

When ART is not a magic bullet: Tailored care for vulnerable people living with hiv in the era of treat-all in Shinyanga, Tanzania

Article

作者: Moyer, Eileen ; de Klerk, Josien ; Erio, Tusajigwe

Community health workers (CHWs) play a crucial role in supporting retention in HIV care in Tanzania under the World Health Organization's Treat-All policy. While the WHO promotes the differentiated service delivery (DSD) model for stable clients, not all people living with HIV (PLHIV) can achieve sustained viral suppression independently. Using ethnographic case studies of one CHW and three vulnerable clients in Shinyanga, Tanzania (2022-2023), we examine how CHWs adapt patient-centred care in the current era of Treat-All. The findings demonstrate that treatment adherence for highly vulnerable groups, particularly children and older adults, relies on collaborative care involving families, neighbours, religious actors, non-governmental organizations, and health providers. CHWs' flexibility and community embeddedness enable them to identify individuals at risk of disengagement and mobilize these care networks. Increased formalization of CHWs within health systems, though beneficial, risks undermining their embeddedness and limiting their capacity to detect need and respond effectively. The study highlights the need for continued financial support for community-based care systems that recognize and support CHWs' relational and moral labour.SGD 3: Good health and well-being.SGD 17: Partnerships for the goals.

2026-07-04·PSYCHOTHERAPY RESEARCH

Physiological, acoustic, and self-reported responses to benign and challenging therapy situations: A pilot study with psychotherapy trainees

Article

作者: Steggles, Kane ; Hughes, Natasha L. ; De Jong, Kim ; Nimphy, Cosima ; Yassen, Noha M. ; Seinen, Tom M. ; Platania, Noemi M.

OBJECTIVE:

: Challenging therapy situations are interpersonally charged moments in therapy and can serve as a critical marker for assessing therapists' interpersonal skills. This study aimed to investigate trainee therapists' stress response during such situations.

METHOD:

: Trainees (n = 46) completed both the Facilitative Interpersonal Skills performance task to measure challenging therapy situations and an additional benign condition depicting interpersonally neutral moments in therapy. We assessed heart rate, heart rate variability, skin conductance level, fundamental frequency, speech rate, and self-reported distress to measure stress throughout the task.

RESULTS:

: Analyses show differences on most outcome measures between the benign and challenging condition in the predicted direction (more arousal), although there was no alignment with self-reported distress.

CONCLUSION:

: These findings highlight the promising nature of considering trainees' stress responses in different therapy situations in future research.

2026-07-01·BIOCHEMICAL PHARMACOLOGY

Exploring the binding kinetics of intracellular allosteric antagonists for CC chemokine receptor 2 — a key to improve insurmountable antagonism

Article

作者: Hartung, Thomas ; Ortiz Zacarías, Natalia V ; Yao, Yao ; den Hollander, Lisa S ; Heitman, Laura H ; Bleijs, Bente ; Grether, Uwe

CC chemokine receptor 2 (CCR2), a class A G protein-coupled receptor (GPCR), represents a promising therapeutic target for inflammatory and autoimmune diseases. Although several CCR2 antagonists have advanced to clinical trials, none have reached the market, largely due to limited efficacy. In recent decades, binding kinetics has emerged as a key consideration in early drug discovery, complementing traditional equilibrium parameters to enhance clinical efficacy. In parallel, targeting allosteric sites offers unique advantages, i.e. insurmountablility, further improving therapeutic safety and efficacy. However, the interplay between binding kinetics and allosterism has received little attention in drug discovery as a strategy to optimize insurmountablility. As such, we developed a kinetic competition association assay, employing the intracellular allosteric radioligand [³H]LUF7482, which displayed high affinity in both equilibrium and kinetic binding assays, with consistent nanomolar K_D values. After validation of the kinetic assay with unlabeled LUF7482, we profiled five known intracellular CCR2 antagonists, including the covalent binder LUF7834 as a positive control, which displayed an apparent long residence time (RT) of 576 min. Functional cAMP assays further revealed a strong correlation between binding kinetics and the extent of insurmountable antagonism. Together, this study established the competition association assay as a robust approach to characterize the kinetic profiles of intracellular CCR2 antagonists, and revealed a clear correlation between binding kinetics and insurmountability. These findings may guide the selection and optimization of next-generation allosteric antagonists targeting CCR2, or the other GPCRs, in drug discovery pipelines, with the aim of improving insurmountability and, consequently, clinical efficacy.

126

项与 University of Leiden 相关的新闻（医药）

2026-05-19

·浙江大学药学院

医药联动 | 莱顿大学Jacques Neefjes院士进校园系列活动

医药联动-邵医讲堂时间：5月22日下午14:00 地点：邵逸夫医院7号楼2楼202胡医师报告题目：From Antigen Presentation to Detoxified Cancer Treatments 主讲人：Jacques Neefjes院士主持人：宋章法浙江大学医学院附属邵逸夫医院副院长热忱欢迎大家参加医药联动活动通知来源 | 邵逸夫医院审核 | 杨慧蓉点击名片，关注我们

2026-05-19

·浙江大学药学院

Jacques Neefjes 院士开讲 | 浙江大学“海外名师大讲堂”第212期暨药学院“黄鸣龙/黄鸣驹”弘药讲坛第19期

化学生物学与肿瘤毒理学交叉融合研发低毒高效新型蒽环药物既破解损伤心脏的生理 “伤心” 隐患又抚慰肿瘤患者治疗的心理 “伤心” 困境 5月23日（周六）荷兰皇家艺术与科学院院士莱顿大学讲席教授 Jacques Neefjes教授走进校园联动药学青年师生开展深度对话在学校国际合作与交流处大力支持下浙江大学“海外名师大讲堂”第212期暨药学院“黄鸣龙/黄鸣驹”弘药讲坛第19期热忱欢迎各位师生参加主讲人 Jacques Neefjes l Jacques Neefjes教授现任荷兰莱顿大学医学中心化学-免疫学讲席教授、荷兰皇家艺术与科学学院院士，其开创性研究横跨化学生物学、细胞生物学、免疫学与肿瘤学四大领域。他在抗原呈递机制方面的奠基性发现，尤其是MHC I类和II类分子介导的抗原加工与呈递过程，深刻揭示了抗病毒与抗肿瘤免疫应答的核心规律，并据此开创了放射免疫治疗这一全新领域。主题报告 Detoxify the Red Death for Better Cancer Treatments 让化疗不再“伤心”：机制创新驱动的蒽环药物减毒优化 l 通过将化学生物学与肿瘤药理学深度融合，Jacques Neefjes教授发现了蒽环类药物的全新作用机制——组蛋白离散介导的染色质损伤。他发现蒽环类化疗药物可通过组蛋白离散诱导“染色质损伤”的新机制，突破传统DNA损伤理论框架。在此基础上，进一步阐明DNA损伤与染色质损伤协同导致心脏毒性的分子机制，解决了该领域长期存在的关键科学问题。基于机制驱动策略，成功开发出低毒高效的新型蒽环药物，并推动相关成果在复发难治性急性髓系白血病中的临床应用及国际多中心III期临床试验，显著提升患者生存获益。相关成果发表在Nature Communications、Nature Chemical Biology、PNAS和Molecular Cancer。主持人王毅浙江大学求是特聘教授药学院常务副院长热忱欢迎师生参加对话交流活动时间：5月23日（周六）14:00 活动地点：药学院349报告厅请扫描报名，我们将预留座位哦论坛背景时光荏苒，回望学院百十余年历史长河，无数灿若星辰的名字闪烁其中从救亡图存到烽火连天，从改革建设到争创一流，无数药学先辈们始终将个人命运与国家发展、民族复兴紧密相连，药济天下苍生，德育桃李芬芳，坚持家国所需，心之所向，以我将无我之姿守护人民生命健康，以求是创新之魂闯出引领世界高度。 2022年起，学院开设“黄鸣龙/黄鸣驹”弘药讲坛。讲坛邀请国内外顶尖学者开设讲座和交流，以此弘扬科学家精神和教育家精神，赓续“求是创新”和“明德弘药”的精神血脉，促进新药源头创新与临床转化。往期讲者包括浙江大学李兰娟院士、美国西北大学John Rogers院士、四川大学魏于全院士、上海交通大学邓子新院士、中国科学院杭州医学研究所谭蔚泓院士、浙江工业大学郑裕国院士、长春应用化学研究所陈学思院士、中国科学院过程工程研究所马光辉院士、浙江大学蔡秀军院士、美国德州大学奥斯汀分校Jonathan Sessler院士、以色列特拉维夫大学Ehud Gazit院士、美国德州大学奥斯汀分校Nicholas Peppas、西班牙圣地亚哥·德孔波斯代拉大学Maria J. Alonso院士、新加坡国立大学Xiaoyuan Chen院士、诺贝尔奖得者Arieh Warshel院士、牛津大学Dame Molly Stevens等国内外顶尖学者和专家等国内外顶尖学者和专家。黄鸣龙先生，江苏扬州人。有机化学家和药物化学家，有机化学人名反应中国第一人，攻克了我国无法合成激素的难关。1918年于浙江公立医药专门学校药科毕业，曾前往德国、英国、美国等多国学习深造。1925-1934年任浙江公立医药专门学校药科教授、主任。1955年当选为中国科学院学部委员，曾任中国科学院上海有机化学研究所研究员，中国药学会名誉理事长。他毕生致力于有机化学的研究，特别是甾体化合物的合成研究，为我国有机化学的发展和甾体药物工业的建立以及科技人才的培养做出了突出贡献。黄鸣驹先生，江苏扬州人。我国近代毒物分析化学奠基人和开拓者、著名药学教育家、中国近代法医学有重大贡献的三位先驱之一。1918年毕业于浙江省医药专门学校药科，曾前往德国、奥地利等多国深造。1949年任浙江省立医学院院务委员会主任，代行院长职务负责领导学校工作。1956任第二军医大学药学系主任。毕生从事毒物分析研究，为开创我国近代毒物分析化学的研究和药学事业的发展作出了重要贡献。供稿 | 徐潇审核 | 杨慧蓉点击名片，关注我们

2026-05-19

·Business Wire

Azafaros Strengthens Leadership Team With Appointment of Amy Sullivan as Chief Financial Officer

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a private company building a portfolio to become a leader in Lysosomal Storage Disorders and focused on addressing neurological symptoms, today announced that Amy Sullivan has joined the company as Chief Financial Officer. "Her expertise in financing, strategic positioning and transaction execution will be instrumental as we advance our Phase 3 studies with nizubaglustat", said Stefano Portolano, CEO at Azafaros. Ms. Sullivan brings more than 30 years’ experience in the life sciences sector, with expertise in capital raising, corporate strategy and communications. She joins Azafaros from IO Biotech, where she served as Chief Financial Officer. “Amy is a highly accomplished financial leader with a strong track record of supporting growth-stage biotech companies,” said Stefano Portolano, Chief Executive Officer at Azafaros. “Her expertise in financing, strategic positioning and transaction execution will be instrumental as we advance our Phase 3 studies with nizubaglustat and continue to build Azafaros as we prepare to file for drug marketing authorization and launch in GM1/GM2 and NPC.” “I am excited to join Azafaros at such an important stage in the company’s development,” said Ms. Sullivan. “The company’s focus on addressing serious neurological manifestations of rare diseases, combined with its strong scientific foundation, represents a compelling opportunity. I look forward to being part of the team who are continuing to drive the company’s growth, while providing new opportunities for patients living with rare diseases.” Prior to IO Biotech, Ms. Sullivan was Chief Financial Officer at TABA, BV. and Chief Strategy Officer at Euronext-listed Kiadis Pharma, where she led a fundraising and capital formation strategy and played a key role in the company’s acquisition by Sanofi. Earlier in her career, she held senior roles at Keryx Biopharmaceuticals and other leading biotech companies, with responsibilities including investor relations, corporate communications and public affairs, supporting periods of significant growth, product commercialization and strategic transactions. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick type C disease (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick type C disease (NPC) Niemann-Pick type C disease is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of the disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.

高管变更孤儿药快速通道

100 项与 University of Leiden 相关的药物交易

登录后查看更多信息

100 项与 University of Leiden 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年06月09日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

LEI-401 ( NAPE-PLD )	肥胖更多	临床前
LEI-515 ( MAGL )	疼痛更多	临床前
JYQ-164 ( PARK7 )	肿瘤更多	临床前
Chimeric macrocyclic peptide 3a ( Bacterial outer membrane proteins )	革兰氏阴性菌感染更多	临床前
Cytochalasins D(Leiden University) ( CFL1 )	肿瘤更多	临床前